Not a registered user? REGISTER

Nurse Practitioner Healthcare Foundation

Continuing Education Program

Opioid Prescribing: Safe Practice, Changing Lives - Update 2016
Disturbing Trends, New Guidelines, Management Challenges

Presented by:  Alan P. Agins, Ph.D.  &  Jody Agins, MSN, RNP, FNP/GNP-BC

A continuing education program for nurse practitioners (NPs) and RNs approved for 2.0 ANCC contact and pharmacology hours

Course Objectives:

  • Highlight recent statistics and trends related to opioid use and misuse in the United States.
  • Review key elements of the CDC Guideline for Prescribing Opioids for Chronic Pain released March, 2016 and discuss the impact of these recommendations on your practice as they relate to pain management for your patients.
  • Discuss important “do’s and don’ts” when considering opioids for pain management.
  • Explore relevant clinical cases related to opioid prescribing, including dosage calculation and opioid rotation, patient/family education around administration of Naloxone, and safely discontinuing opioids.

Release Date: December 1, 2016

Expiration Date:  November 30, 2019

The Nurse Practitioner Healthcare Foundation is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity is supported by an independent educational grant from the ER/LA Opioid Analagesic REMS Program Companies. 

CE Requirements
Requirements for successful completion of this CNE activity include downloading the handout (after registering), viewing all video segments, answering the assessment  questions embedded within the program and completing an online program evaluation. There is no partial credit.

Faculty / Planner Disclosures

  • Alan P. Agins, Ph.D. has no conflicts of interest to report.
  • Jody Agins, MSN, RNP, FNP/GNP-BC has no conflicts of interest to report.
  • Pam Jenkins, MS, NP (Program Director and Lead Nurse Planner for NPHF) has no conflicts of interest to report.


The information presented in this program is solely for educational purposes and should not be construed as specific instructions for the diagnosis or treatment of patients. Utilization of any information, derived from this program, in patient care remains strictly the professional responsibility of the health care provider. The health care provider is further advised to: (1) ascertain current FDA status of each drug and (2) consult current drug information guides, manufacturer product information or package inserts regarding the proper use, dosages, dosing schedules, contraindications, warnings and other pertinent prescribing and safety information. The Faculty (Alan Agins amd Jody Agins) disclaim any liability, loss, injury or damage incurred as a consequence, directly or indirectly, from the use and application of any of the contents of this program. During the "Program" there may be occasional mention of proprietary or brand-name drugs. The mention or appearance of a specific proprietary product name should not be construed by the viewer that the Faculty, NPHF or CO*RE endorse or have specific bias toward that product or its manufacturer. Similarly, the absence of mention of a specific brand name should not imply that the product is deemed inferior to others in its class